Journal article
Evaluation of follistatin as a therapeutic in models of skeletal muscle atrophy associated with denervation and tenotomy
PV Sepulveda, S Lamon, A Hagg, RE Thomson, CE Winbanks, H Qian, CR Bruce, AP Russell, P Gregorevic
Scientific Reports | NATURE PORTFOLIO | Published : 2015
DOI: 10.1038/srep17535
Abstract
Follistatin is an inhibitor of TGF-β superfamily ligands that repress skeletal muscle growth and promote muscle wasting. Accordingly, follistatin has emerged as a potential therapeutic to ameliorate the deleterious effects of muscle atrophy. However, it remains unclear whether the anabolic effects of follistatin are conserved across different modes of non-degenerative muscle wasting. In this study, the delivery of a recombinant adeno-associated viral vector expressing follistatin (rAAV:Fst) to the hind-limb musculature of mice two weeks prior to denervation or tenotomy promoted muscle hypertrophy that was sufficient to preserve muscle mass comparable to that of untreated sham-operated muscle..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
This work was supported by Project Grant funding from the National Health and Medical Research Council (NH&MRC) of Australia (526648 awarded to PG). PG is supported by a NH&MRC Career Development Fellowship (1046782) and previously, a Senior Research Fellowship sponsored by Pfizer Australia. The Baker IDI Heart & Diabetes Institute is supported in part by the Operational Infrastructure Support Program of the Victorian Government.